
zzso zzso zzso zzso zzso zzso are being used with increasing frequency in the settings of zzso coronary interventions and acute zzso zzso The development of zzso after zzso zzso blockade has been observed to some extent with all zzso zzso zzso zzso studied to date and could potentially limit their zzso The zzso and severity of zzso has varied in large clinical trials with zzso zzso zzso presumably as a consequence of the different structural and zzso characteristics of the agents, the dose administered and duration of use, repetition of exposure, and the various drugs zzso with these zzso Certain baseline characteristics may be zzso In most cases, severe zzso associated with the use of zzso zzso zzso zzso was readily zzso with zzso zzso and was not usually associated with major clinical zzso Although the exact mechanisms responsible for zzso after zzso zzso blockade are poorly zzso an immune mechanism is suggested in which the binding of the zzso to zzso zzso receptors leads to the exposure of zzso binding sites recognized by zzso or induced zzso zzso the zzso zzso complex itself may induce an immune zzso All patients receiving zzso zzso zzso zzso should be monitored within 24 hours of initiation of therapy for the development of zzso An zzso for the detection and management of zzso after zzso zzso inhibitor therapy is zzso 

